1.67
-0.60%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Luye Pharma Group
Its shares trade on HKEX under the ticker 2186.HK. It has been listed since 9 July 2014. In the fiscal year to 31 December 2025, it reported revenue of CN¥7.35bn and net income of CN¥720.9m. At that date it held total assets of CN¥38.26bn and shareholders' equity of CN¥18.73bn.
Luye Pharma Group Ltd. is an investment holding company, which engages in the developing, producing, marketing, and selling pharmaceutical products. The company is headquartered in Yantai, Shandong. The company went IPO on 2014-07-09. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer’s disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The firm operates its business mainly in Mainland China.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Jul 2014
- Employees
- 4,822
- Website
- luye.cn ↗
Leadership
Pay as last reported
- Mr. Dian Bo LiuExecutive Chairman of the Board, Chief Executive OfficerCN¥3.2m
- Mr. Rong Bing YangExecutive Vice Chairman of the Board, since 2003CN¥1.8m
- Mr. Yuan Chong LiuChief Financial Officer
- Ms. Li LiVice President - Sales and Marketing Management
- Mr. Hui Xian YuanExecutive DirectorCN¥978,000
- Ms. Yuan Yuan ZhuExecutive Director, since 2014CN¥1.2m
- Ms. Mei Yi LeeCompany Secretary
- Mr. Liming HuangNon-Executive Director
- Mr. Rui Lin SongNon-Executive DirectorCN¥274,000
- Mr. Sze Chung ChoyNon-Executive Independent DirectorCN¥274,000
- Mr. Man Kit LeungNon-Executive Independent DirectorCN¥329,000
- Prof. Yuk Lam LoNon-Executive Independent DirectorCN¥274,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 65
- Environment
- 82
- Social
- 58
- Governance
- 56
- Direct emissions (scope 1)
- 10,755.273 t
- Energy emissions (scope 2)
- 65,446.08 t
- Women in the workforce
- 53.09298%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Luye Pharma Group Ltd has several strengths that contribute to its success in the market. The company has a diverse portfolio of pharmaceutical products, allowing it to cater to a wide range of medical needs. Additionally, Luye Pharma Group has a strong presence in both domestic and international markets, leveraging its global reach for growth and expansion.
- Furthermore, the company has established strategic partnerships and collaborations with various healthcare organizations, enabling Luye Pharma Group to access new markets, technologies, and distribution channels. This strengthens its competitive advantage and enhances its overall market position.
Weaknesses
- Despite its strengths, Luye Pharma Group Ltd also faces certain weaknesses that may hinder its progress. One weakness is its heavy reliance on a few key products for revenue generation. This concentration of sales poses a potential risk if market conditions change or if new competitors enter the market.
- In addition, the company may face challenges in terms of regulatory compliance and intellectual property protection, especially when operating in different jurisdictions. These weaknesses could impede Luye Pharma Group's growth prospects and expose it to legal and regulatory risks.
Opportunities
- Luye Pharma Group Ltd has various opportunities that it can capitalize on to further expand its business. The growing global pharmaceutical market presents significant potential for revenue growth. By leveraging its strong R&D capabilities, the company can develop innovative drugs to address unmet medical needs and tap into new therapeutic areas.
- Furthermore, Luye Pharma Group can consider strategic acquisitions and partnerships to enhance its product portfolio and market presence. Collaborations with research institutions and universities can also provide access to cutting-edge technology and expertise, facilitating continued innovation and growth.
Threats
- Luye Pharma Group Ltd faces threats that could pose risks to its business operations and market position. Intense competition within the pharmaceutical industry, both from existing players and emerging companies, presents a challenge for the company. This competition can potentially impact Luye Pharma Group's market share and pricing strategy.
- Additionally, the regulatory landscape and pricing pressures in different markets may affect the company's profitability. Changes in regulations, such as drug approval processes or pricing policies, can create uncertainties and increase operational costs for Luye Pharma Group.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.